Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients

Clinical Chemistry

Volumn 44, Issue 4, 1998, Pages 858-862

  Huengsberg, Mia ^a   Winer, John B ^b   Compels, Mark ^c   Round, Rachel ^a   Ross, Jonathan ^a   Shahmanesh, Mohsen ^a  

^a Whittall Street Clinic ^*  (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TRYPTOPHAN METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031900585     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.4.858     Document Type: Article

References (23)

1. Hortin GL, Landt M, Powderly WG. Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem 1994; 40(5):785-9.
2. Perkins MN, Stone TW. Pharmacology and regional variations of quinolinic acid-evoked excitations in rat central nervous system. J Pharmacol Exp Ther 1983;226:551-7.
3. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991;29(2):202-9.
4. Werner ER, Bitterlich G, Fuchs G, Service FJ, O'Brien PC, Grina, LH. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987;41:273-80.
5. Saito K, Lackner A, Markey SP, Heyes MP. Cerebral cortex and lung indoleamine 2,3-dioxygenase activity is increased in type D retrovirus infected macaques. Brain Res 1991;540:353-4.
6. Heyes MP, Saito K, Markey S. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 1992; 283:633-5.
7. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990;3(9): 873-6.
8. Winer JB, Bang B, Clarke JR, Knox K, Cook TJ, Gompels M, et al. A study of neuropathy in HIV infection. Q J Med 1992;83(302): 473-88.
9. Dyck PJ, Sherman WR, Hallcher LM, Hausen A, Reibnegger G, Szabo G. Human diabetic endoneural sorbitol, fructose and myoinositol related to sural nerve morphometry. Ann Neurol 1980;8: 590-6.
10. Atherton ND, Green A. HPLC measurement of phenylalanine in plasma. Clin Chem 1988;34(11):2241-4.
11. Holmes EW. Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high-performance liquid chromatography. Anal Biochem 1988;172:518-25.
12. Fuchs D, Moller AA, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich, MP, Wachter H. Increased endogenous interferon-γ and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 1991;28(3):207-11.
13. Fuchs D, Forsman A, Hagberg L, Larsson M, Norkrans G, Reibnegger G, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 1990;10(6):599-603.
14. Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retrovir 1994;10(8):947-51.
15. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:329-37.
16. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS [Review]. Adv Exp Med Biol 1991;294:425-35.
17. Larsson M, Hagberg L, Norkrans G, Forsman A. Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection. J Neurosci Res 1989; 23(4):441-6.
18. Shor-Posner G, Feaster D, Blaney NT, Rocca H, Mantero-Atienza E, Szapocznik J, et al. Impact of vitamin B6 status on psychological distress in a longitudinal study of HIV-1 infection. Int J Psychiatry Med 1994;24(3):209-22.
19. Heyes MP, Brew BJ, Saito K, Quearry BJ, Price RW, Lee K, et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and β-2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 1992; 40(1):71-80.
20. Fuchs D, Gisslen M, Larsson M, Norkrans G, Hagberg L, Wachter H. Increase of tryptophan in serum and in cerebrospinal fluid of patients with HIV infection during zidovudine therapy. Adv Exp Med Biol 1996;398:131-4.
21. Sardar AM, Reynolds GP. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett 1995;187(1):9-12.
22. Heyes MP, Mefford IN, Quearry BJ, Dedhia M, Lackner A. Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: relationship to clinical and viral status. Ann Neurol 1990;27(6):666-75.
23. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115(Part 5):1249-73.